T/R potency <5% [Regulatives / Guidelines]

posted by Achievwin – US, 2022-09-07 22:50 (198 d 22:50 ago) – Posting: # 23277
Views: 1,352

❝ ❝ Somewhere in the Bioequivalence guidance I remembered that when designing the studies we try to keep T/R potency +/-5%. Can someone point out where this kind of condition existed, (latest guidance has no mention of this)


❝ – AFAIK, it was never stated by the FDA in any guidance.


It was there in 2001 guidance as desired requirement-not mandatory... problem is that I can not find that 2001 (first) BE/BA guidance
I can not find that 2001 (first) BE/BA guidance. Also in 2021 guidance lines 807-808

Complete thread:

UA Flag
Activity
 Admin contact
22,551 posts in 4,724 threads, 1,606 registered users;
10 visitors (0 registered, 10 guests [including 4 identified bots]).
Forum time: 20:41 CET (Europe/Vienna)

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5